News

Newly approved antibody could offer another option for protecting infants from RSV, a common infection that can be deadly
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...
Scripps News on MSN15h
FDA Approves Merck’s Enflonsia to prevent RSV in infants
The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...
New antibody shot could help protect babies from RSV
A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...
Clinical Trials Arena1d
MSD’s Enflonsia receives FDA approval for RSV prophylaxis
Merck’s Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...
PharmExec2d
FDA Approves Merck’s Enflonsia to Prevent Respiratory Syncytial Virus
Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...
Fierce Pharma3d
Merck scores FDA nod for Enflonsia, setting up RSV market battle vs. Sanofi and AstraZeneca's Beyfortus
Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...
Zacks Investment Research on MSN2d
Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants
Merck MRK announced FDA approval for its prophylactic long-acting monoclonal antibody, clesrovimab, for the prevention of RSV ...
MPR2d
Enflonsia Approved for RSV Disease Prevention in Infants
The Food and Drug Administration (FDA) has approved Enflonsia ™ (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who ...
Pharmaceutical Technology on MSN2d
MSD receives FDA approval for Enflonsia to prevent RSV
MSD has received FDA approval for Enflonsia (clesrovimab-cfor) to prevent respiratory syncytial virus (RSV) in neonates and ...